The DUSP3 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the DUSP3 gene in the NCI-H1299 human lung epithelial carcinoma cell line. This polyclonal model retains genetic diversity while enabling loss-of-function studies of DUSP3 in lung cancer biology.
NCI-H1299 is a TP53-null, KRAS wild-type cell line derived from lymph node metastasis of lung adenocarcinoma, widely used as a model for non-small cell lung cancer (NSCLC). Its metastatic origin and p53 deficiency make it suitable for investigating tumor progression and MAPK-dependent signaling in a clinically relevant context.
DUSP3 encodes a dual-specificity phosphatase that dephosphorylates phosphotyrosine and phosphoserine/threonine on ERK1/2 and JNK, functioning as a negative regulator of MAP kinase signaling. Activated downstream of EGFR, EGR1, and oxidative stress, DUSP3 interacts with MAPK1, MAPK8, STAT5A, and NPM1 to attenuate signal transduction. Knockout of DUSP3 leads to sustained phosphorylation of ERK and JNK, promoting the activity of transcription factors ELK1, c-JUN, and STAT5A/B, and thereby upregulating proliferation and survival programs. This hyperactivates the RAS?CRAF?CMEK?CERK/JNK cascade.
In the TP53-null NCI-H1299 context, DUSP3 loss amplifies MAPK pathway output, disrupting the balance between proliferation and apoptosis. The combined deficiency of p53-mediated checkpoints and enhanced ERK/JNK signaling provides a powerful system to study how phosphatase inactivation cooperates with genomic instability in NSCLC. This model enables dissection of DUSP3??s role in modulating growth, survival, and migration in metastatic lung cancer cells.
Applications include Western blotting and RT-qPCR for DUSP3 and phospho-ERK/JNK analysis, MTT and annexin V assays for proliferation and apoptosis, transwell assays for migration/invasion, and phospho-kinase profiling to map signaling changes. Drug sensitivity screening identifies therapeutic vulnerabilities, and RNA sequencing reveals transcriptome-wide consequences of DUSP3 loss. This polyclonal knockout cell population is suited for target validation, signal transduction studies, and functional genomics in lung cancer. For additional information, please contact Ascent Research.
